Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment combination for adults with advanced small cell lung cancer SCLC. The study compares a medicine called obrixtamig combined with standard treatment atezolizumab, carboplatin, and etoposide against the standard treatment alone. Obrixtamig is an antibody-like molecule designed to help the immune system fight cancer. The study also tests a new medical device to measure levels of a tumor marker called DLL3. Participants are randomly assigned to one of two groups. One group receives obrixtamig plus the standard treatment, while the other group receives only the standard treatment. All drugs are given through infusions into a vein. Participants in the obrixtamig group stay overnight at the study site after their first two obrixtamig treatments. The study lasts for up to three years, during which participants visit the study site regularly. Throughout the study, doctors monitor tumor size to compare results between groups. They also check participants overall health and note any side effects. Researchers measure outcomes such as overall survival, progression-free survival, symptom changes, treatment responses, and any treatment-related side effects. Participants are closely observed for up to 36 months to evaluate these effects and safety.
Actively Recruiting
Researchers are conducting a randomized, multicenter, multinational, double-blind Phase 3 study comparing MB11, a proposed nivolumab biosimilar, with EU- and US-sourced Opdivo in adults with previously untreated advanced unresectable or metastatic melanoma. The study aims to evaluate and compare the pharmacokinetics, efficacy, safety, and immune response of MB11 versus Opdivo as first-line treatment. Participants receive one of three study drugs MB11, EU-Opdivo, or US-Opdivo. During the first 12 treatment cycles, each is given as a 3 mgkg intravenous infusion over 30 minutes every two weeks. From Cycle 13 onwards, dosing continues either at 3 mgkg IV every two weeks or a flat dose of 240 mg IV every two weeks. The study treatment period covers at least 24 weeks for primary evaluation and up to 52 weeks for extended assessments. During the study, participants undergo regular assessments including tumor measurements by CT or MRI, biopsies for PD-L1 testing, and laboratory evaluations of organ function. Researchers monitor pharmacokinetics, efficacy, safety, and immunogenicity over the treatment period. Participants are followed through scheduled visits with evaluations up to one year, with continued safety monitoring and data collection until study completion in 2029.